Insurers Running Medicare Advantage Plans Overbill Taxpayers By Billions As Feds Struggle To Stop It
An enhanced government effort to catch insurers that overcharge Medicare faces resistance from the insurance industry.
Feds Want To Show Health Care Costs On Your Phone, But That Could Take Years
Giving consumers more knowledge about the costs of care has long been desired, but administration officials cautioned it could take two years or more for useful data to appear in a phone app.
Pain Clinics’ Doctors Needlessly Tested Hundreds Of Urine Samples, Court Records Show
Whistleblower lawsuits accuse Tennessee chain of bilking millions from Medicare for unnecessary urine drug tests.
New Rules Will Ease Patients’ Access To Electronic Medical Records, Senate Panel Says
Sen. Lamar Alexander (R-Tenn.), head of the influential HELP committee, wants to make it easier to share and store detailed medical histories.
FDA Chief Calls For Stricter Scrutiny Of Electronic Health Records
In an interview, FDA Commissioner Scott Gottlieb reacts to a KHN/Fortune investigation of the drawbacks and risks of electronic health records.
Death By 1,000 Clicks: Where Electronic Health Records Went Wrong
The U.S. government claimed that turning American medical charts into electronic records would make health care better, safer and cheaper. Ten years and $36 billion later, the system is an unholy mess. Inside a digital revolution that took a bad turn.
Feds Settle Huge Whistleblower Suit Over Medicare Advantage Fraud
A DaVita subsidiary will pay $270 million over allegations that it cheated the federal government for years.
Avoidable Sepsis Infections Send Thousands Of Seniors To Gruesome Deaths
No one tracks sepsis cases closely enough to know how often these severe infections turn fatal. But the toll — both human and financial — is enormous, finds an investigation by KHN and the Chicago Tribune.
Rudy Giuliani’s Consulting Firm Had Hand In Halting Florida’s Opioid Investigation
Post-9/11, Giuliani Partners helped craft a plan that put a halt to a probe into Purdue’s marketing of OxyContin.
Purdue Pharma’s Sales Pitch Downplayed Risks Of Opioid Addiction
Through a widely circulated brochure and a videotape of testimonials, the maker of OxyContin stressed patients’ right to opioid treatment for pain.